BillionToOne raised $130 million in a Series D funding round led by Premji Invest to expand and scale their prenatal and oncology businesses.
BillionToOne raised $130 million in a Series D funding round led by Premji Invest to expand and scale their prenatal and oncology businesses.
01/13/25, 11:37 AM
Location
menlo parkMoney raised
$130 million
Round Type
series d
Investors
Fifty Years, Libertus Capital, Civilization Ventures, Hummingbird Ventures, Baillie Gifford, Adam Street Partners, Neuberger Berman, Premji Invest
In June 2024, BillionToOne successfully raised $130 million in an oversubscribed Series D funding round. The funds will be utilized for the expansion and scaling of their prenatal and oncology businesses.
Company Info
Location
menlo park, california, united states
Additional Info
BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules at the single-count level. BillionToOne's flagship product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood. BillionToOne was co-founded by Oguzhan Atay, Ph.D. and David Tsao, Ph.D. For more information, visit www.billiontoone.com.